New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Bolt Biotherapeutics, Inc. (BOLT) vs Citius Pharmaceuticals, Inc. (CTXR)

Bolt Biotherapeutics, Inc. and Citius Pharmaceuticals, Inc. are both Biotechnology companies. Bolt Biotherapeutics, Inc. and Citius Pharmaceuticals, Inc. are of similar size ($13.7M and $13.2M). Citius Pharmaceuticals, Inc. has the higher net margin (0.00% vs −611.5%) and the higher return on invested capital (−58.7% vs −154.8%). Across the 13 metrics below, Citius Pharmaceuticals, Inc. leads on 9 and Bolt Biotherapeutics, Inc. on 4.

Valuation

Metric BOLT CTXR Biotechnology median
P/E n/m n/m 8.49
P/S 2.07 — 8.56
P/B 1.14 0.18 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA n/m n/m 0.69
EV/Sales 2.64 — 8.00
Earnings yield (301.80%) (418.29%) (35.81%)
Free cash flow yield (247.02%) (261.25%) (25.41%)

Profitability

Metric BOLT CTXR Biotechnology median
Gross margin 100.00% — 70.18%
Operating margin (654.53%) 0.00% 0.00%
Net margin (611.47%) 0.00% 0.00%
Free cash flow margin (655.72%) 0.00% 0.00%
Return on equity (127.96%) (64.51%) (51.58%)
Return on assets (51.70%) (34.29%) (45.91%)
Return on invested capital (154.77%) (58.74%) 0.00%

Growth

Metric BOLT CTXR Biotechnology median
Revenue growth (TTM) 12.79% — 7.20%
EPS growth (last fiscal year) 45.91% 43.38% 29.04%
Revenue growth, 5-year CAGR 101.61% — 9.54%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric BOLT CTXR Biotechnology median
Debt to equity 2.06 0.08 0.00
Current ratio 2.05 0.84 4.79
Net debt to EBITDA 0.21 0.11 1.01

Dividend

Metric BOLT CTXR Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric BOLT CTXR Biotechnology median
Market cap 13.20m 13.65m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack